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Abstract
Introduction: Tibolone is a synthetic steroid, used with increasing frequency to treat symptoms of menopause,
including patients with solid-organ transplants who are taking concurrent immune suppression. To the best of our
knowledge, there are no reported drug interactions between tibolone and tacrolimus, one of the principal immune
suppressants used in kidney transplantation.
Case presentation: We report the case of a 49-year-old Caucasian woman who had received a kidney transplant
and who developed acute kidney injury secondary to tacrolimus toxicity 10 days after starting tibolone therapy. No
alternative causes were found. Tibolone is known to be a weak competitive inhibitor of CYP3A4, which is involved
in tacrolimus metabolism.
Conclusions: Despite a careful evaluation, no alternative reason was found for the acute kidney injury, and her
kidney function returned to the previous baseline within several days of cessation of the medication, and with no
other specific treatment. Using the Drug Interaction Probability Scale we conclude that she experienced a probable
drug interaction. We believe that transplant clinicians should utilise frequent therapeutic drug monitoring of
tacrolimus in patients starting or stopping tibolone therapy.
Introduction
Tibolone is a synthetic steroid with estrogenic, andro-
genic and progestagenic properties. It is indicated for
relief of the symptoms of menopause in many countries
and has been used in Europe for nearly 20 years [1], but
is gaining in use elsewhere in the world including Aus-
tralia. Tibolone use may be increasing following the
recent widely-publicised results of the Women’s Health
Initiative (WHI) study [2], which has resulted in a
reduction in the use of conventional estrogen-containing
hormone replacement therapy (HRT) [3]. Steroid-
induced osteoporosis remains a significant problem in
solid-organ transplantation, and it is likely that HRT
will continue to be utilized for the prevention of osteo-
porosis in these patients. Tibolone therapy has been
suggested as an alternative to conventional HRT [4] but
its role remains unclear, particularly after the recent
publication of the Long-Term Intervention on Fractures
with Tibolone (LIFT) trial, which showed that although
tibolone reduced the risk of fracture and breast cancer,
it increased the risk of stroke in older women [5]. We
report a case in which a woman who had been the reci-
pient of a kidney transplant with stable allograft func-
tion on tacrolimus-based immunosuppression,
developed acute kidney injury secondary to tacrolimus
toxicity 10 days after starting tibolone therapy. This
resolved completely on cessation of the drug. We sug-
gest that this may have been due to a drug interaction
between tibolone and tacrolimus, which has not
previously been reported.
Case presentation
A 49-year-old Caucasian woman presented with an
acute deterioration in her allograft function seven years
after she underwent a deceased-donor kidney transplant
for end-stage kidney disease, secondary to autosomal
dominant polycystic kidney disease. Her transplant was
a three human leukocyte antigen (HLA) mismatch to an
unsensitised recipient. The initial therapy was standard
immunosuppression at that time (cyclosporin, mycophe-
nolate mofetil and prednisolone). The transplantation
was complicated by acute rejection after one year due to
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any medium, provided the original work is properly cited.steroid withdrawal, which was treated with reinstitution
of steroids and conversion to tacrolimus therapy one
year later. This was some five years prior to her current
presentation. Her serum creatinine concentration then
stabilized at 125 μmol/L. She subsequently developed
osteoporosis and was commenced on calcitriol and alen-
dronate. She was prescribed HRT in the form of estra-
diol and norethisterone for both the symptoms of
menopause and for protection of her bones. In 2002
after the publication of the WHI study [2], she
approached her general practitioner and requested to be
withdrawn from HRT, which subsequently occurred
over the next two months.
In early 2007, she presented to our transplant centre
with lethargy, difficulty sleeping and anxiety over a
period of one week. She had no recent illness. Her
medications at this time included: tacrolimus 1.5 mg in
the morning and 2 mg at night, prednisolone 4 mg
daily, mycophenolate mofetil 500 mg twice daily, ator-
vastatin 20 mg daily, alendronate 70 mg weekly, ome-
prazole 20 mg daily, citalopram 20 mg daily, calcium
carbonate 600 mg daily, calcitriol 0.25 μg daily and
folic acid 5 mg daily. The only change to her medica-
tions had been the addition of tibolone therapy
(2.5 mg per day) for the symptoms of menopause 10
days prior to presentation. On examination she was
apyrexial, but was noted to be extremely tremulous
and was newly hypertensive with a blood pressure of
144/96 mmHg (previous blood pressure: 118/74
mmHg). She was hyperglycemic with a blood sugar of
12.1 mmol/L, having not been diabetic previously (fast-
ing glucose: 4.5 mmol/L). There was no abnormality
found on examination of her cardiovascular, respira-
tory or gastrointestinal systems. She was found to have
worsening graft function with a serum creatinine level
of 177 μmol/L (previously 120 μmol/L) and to have
tacrolimus toxicity with a level of 17.9 μg/L (liquid
chromatography with tandem mass spectrometry
(LC-MS/MS) performed at the transplant centre, see
Figure 1), having previously been 5.2 μg/L (enzyme
immunoassay (MEIA) performed at a local pathology
c e n t r e ) .S h ew a ss e r o l o g i c a l l yp o s i t i v ef o rB Kv i r u sb u t
below the threshold of clinical significance (1 × 10
3 at
our institution), with a quantitative polymerase chain
reaction (PCR) level of 1.7 × 10
2, which had been noted
for several months previously and had not changed.
Management included ceasing tibolone and reducing
the tacrolimus dose to 0.5 mg in the morning and 1 mg
at night until the concentration reduced to target level,
which occurred over the next six days. Her creatinine
level slowly returned to baseline over a period of three
months, at which time her tacrolimus level was 4 μg/L
at a dose of 2.5 mg per day; a similar dosage and drug
level to where she had started.
The differential diagnosis of acute kidney injury
included tacrolimus toxicity, BK nephropathy, acute
rejection and chronic allograft nephropathy. Tacrolimus
toxicity was consistent with the acute nature of the pre-
sentation, explained all of her symptoms and signs and
was borne out by the resolution of her kidney injury as
her tacrolimus level and allograft function returned to
the previous baseline. It was noted that the baseline and
recovery tacrolimus concentrations were measured by
MEIA, compared to LC-MS/MS in our centre. However,
previous studies have shown that MEIA overestimates
tacrolimus concentration in the blood of kidney trans-
plant recipients by 16 to 20 percent [6]. Therefore the
different assay methodologies would be likely to under-
estimate the true size of the effect. BK nephropathy,
acute rejection and chronic allograft nephropathy were
all considered unlikely due to her clinical presentation
and the investigations performed. Although a kidney
transplant biopsy was not performed (due to her rapid
improvement with reduction in tacrolimus dose and ces-
sation of tibolone), none of these three possibilities
would have resolved in this time-frame had they been
the true cause of her kidney dysfunction.
The differential diagnosis of tacrolimus toxicity
included interaction with new medications, overdose of
tacrolimus tablets (either inadvertent or deliberate) and
diarrhea. She had no history of a diarrheal illness or
loose bowel motions. It was considered unlikely that she
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Figure 1 Whole Blood Tacrolimus Concentration versus Time:
note the two different assays used for the tacrolimus
concentration reflecting different methodologies used by the
external pathology provider and our centre.
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Page 2 of 4accidentally overdosed on the tablets as she was known
to be adherent with very consistent blood levels of both
tacrolimus and cyclosporin before that. There had been
no recent dose changes to cause confusion. The only
recent medication had been the tibolone, and although
there are no reported drug interactions with tacrolimus
and tibolone, we considered it possible that the initia-
tion of tibolone had precipitated the tacrolimus toxicity
by some unrecognised mechanism.
Discussion
Tacrolimus is a calcineurin inhibitor immunosuppres-
sive agent which is metabolized in the liver and the gut
by CYP3A4 and CYP3A5 isoenzymes to several metabo-
lites. Tibolone is rapidly metabolized to its three meta-
bolites in the gastrointestinal tract and the liver by 3a/b
hydroxysteroid dehydrogenase. Pharmacokinetic studies
in three healthy volunteers showed that tibolone was a
weak competitive inhibitor of CYP3A4 and CYP2C9,
but the authors concluded that tibolone would be unli-
kely to have a clinically significant effect [7]. Despite
that, tibolone has now been shown to interact with war-
farin (which is a substrate of CYP2C9 and CYP3A4),
requiring dose alterations from 12 to 56 percent in a
number of patients [8]. A study of 16 healthy volunteers
to investigate this potential drug interaction found an
increase in the mean International Normalized Ratio
(INR) of 0.4 [9]. However, marked individual variation
was noted between subjects, with two of the 16 subjects
having a major increase in INR. The authors concluded
that it is advisable to monitor for changes in coagula-
tion status during co-administration of tibolone and
warfarin.
DIPS has recently been developed to provide a guide
to evaluating drug interaction causation in a specific
patient [10]. Our case report is considered a ‘probable’
drug interaction as determined by a DIPS score of 5 or
6 (Table 1). Using this scoring system, our patient
experienced a probable drug interaction between tacroli-
mus and tibolone, and we surmise the likely mechanism
is the effect of each drug on her cytochrome P450
system.
Table 1 Drug Interaction Probability Scale (DIPS)
DIPS Questions Answer Score Comments
1. Are there previous credible reports of this interaction
in humans?
N/A 0 No other case reports exist.
2. Is the observed interaction consistent with the known
interactive properties of precipitant drug?
Yes/
Unknown
1/0 Given the evidence of tibolone’s interaction with warfarin, and
the individual variation seen with that interaction, it is reasonable
to suggest that in some individuals, there are known interactive
properties of the precipitant drug. However, it could also be
argued that there is not enough information regarding the
mechanism of the interaction between tibolone and warfarin to
make this inference.
3. Is the observed interaction consistent with the known
interactive properties of the object drug?
Yes 1 Tacrolimus is certainly known to interact with inhibitors of the
CYP450 system, of which tibolone is known to be one.
4. Is the event consistent with the known or reasonable
time course of the interaction?
Yes 1 Tibolone was started 10 days prior to presentation. As our case
report had been stable for some time on tacrolimus, there was
no baseline blood test. However, the development of the
symptoms consistent with acute tacrolimus toxicity occurred
within a reasonable time course of the start of tibolone use.
5. Did the interaction remit upon dechallenge of the
precipitant drug with no change in the object drug?
N/A 0 Tibolone was ceased immediately, but due to the effects of the
tacrolimus toxicity (acute kidney injury in a transplant patient) the
dose of tacrolimus was also altered.
6. Did the interaction reappear when the precipitant
drug was readministered in the presence of continued
use of the object drug?
N/A 0 She was reluctant to re-challenge with tibolone.
7. Are there reasonable alternative causes for the event? No 1 As discussed above, alternative causes were looked for and none
were found.
8. Was the object drug detected in the blood or other
fluids in concentrations consistent with the proposed
interaction?
Yes 1 See Figure 1 for tacrolimus concentrations.
9. Was the drug interaction confirmed by any objective
evidence consistent with the effects on the object drug
(other than drug concentrations)?
Yes 1 She was hyperglycemic and hypertensive, both known effects of
tacrolimus toxicity. She also displayed a tremor, and had
symptoms of anxiety.
10. Was the interaction greater when the precipitant
drug dose was increased or less when the precipitant
drug dose was decreased?
N/A 0 The tibolone was ceased at presentation and alternate doses
were not used.
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Given the polymorphisms in the cytochrome P450
metabolic pathway and the potential for a wide variation
in the metabolism of these two drugs, there is a strong
likelihood that other patients may experience a similar
interaction. However, given pharmacogenetic variability,
not all patients would be expected to be affected. Pri-
mary care physicians may not seek the advice of trans-
plant specialists for treatment not directly related to the
transplant, and given that there are no reports in the lit-
erature, would not expect a complication such as this.
We believe that all clinicians (transplant and primary
care) should be aware of this probable drug interaction
and should ensure monitoring of tacrolimus concentra-
tion within three days of commencement of tibolone.
Prophylactic dose reduction of tacrolimus is not advised,
as it is not likely that all patients will be affected.
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